Inform Diagnostics (MLS), the leading pathology services provider that
collaborates to make patients and practices better, announced today that
it will have a significant presence at the Annual Meeting for the Large
Urology Group Practice Association (LUGPA), a conference offering roundtable
discussions, hands-on training and health policy updates, on November
7-9 in Chicago, Illinois.
Visitors to MLS’ booth can learn about a new genomic testing protocol
that will help Urologists guide better treatment decisions and determine
outcomes in prostate cancer patients. MLS urologic pathologists can find
evidence of important genetic abnormalities, called biomarkers, through
sophisticated laboratory tests. Understanding the unique genetic profile
of each prostate cancer patient helps clinicians more fully understand
the scope and level of disease, and to optimize outcomes through a personalized
therapy aligned with genetic responsiveness.
In addition, MLS will be presenting important information about forthcoming
regulatory guidance and compliance. MLS technical directors will be available
to help visitors to their booth avoid potential Medicare penalties in
2014 and successfully attest to Meaningful Use requirements. MLS technical
directors can help LUGPA members prepare for Meaningful Use audits by
ensuring adherence to CMS requirements and prepare for the revolution
in medical billing, ICD10.
“Inform Diagnostics has a responsibility to doctors and patients
to deliver reliable, meaningful laboratory results because effective patient
care stems from accurate interpretation and diagnosis, so we’ll
be introducing an exciting innovation in genomic testing protocols,”
said Rajal B. Shah, MD, Director of Urologic Pathology at MLS. “Two
important genetic abnormalities: one characterized by loss of a protective
gene known as PTEN and another by overexpression of the cancer- promoting
gene ERG occur in a staggering 50-60 percent of prostate cancer patients.
Inform Diagnostics helps the clinicians more fully understand the scope
and level of disease, and to optimize outcomes aligned with genetic responsiveness.”
LUGPA holds an annual meeting every fall to provide a forum for discussion
between integrated urology groups on the issues they face including declining
reimbursement, increased complexity of third party contracting, pressure
for adoption of EMR systems and an increasingly burdensome legislative
and regulatory environment at both the state and federal levels. The meeting
offers roundtable discussions, hands-on training and health policy updates.
This year’s meeting, “The Future of Independent Urology: Alive
and Well” will be held at The Drake Hotel in Chicago, November 7-9.
About Inform Diagnostics
Serving more than 3,500 patients each day, Inform Diagnostics is a leader
in providing an academic-caliber pathology laboratory with diagnostic
services in the fields of dermatology, gastroenterology, hematology and
urology. Building upon our experience with health IT, we also offer accessible
technology solutions to assist healthcare professionals as they work towards
accordance with Meaningful Use initiatives.
Inform Diagnostics, a wholly-owned subsidiary of Japan-based Inform Diagnostics Holdings
Inc., employs a talented team of leading pathologists, histologists, lab
technicians, technology consultants, and other medical professionals —
all driven to help provide the highest and most up-to-date levels of diagnostic
quality, enhanced workflow and practice solutions possible. It is part
of our commitment: not only to scientific excellence, but to patients
The Large Urology Group Practice Association (LUGPA) was established with
the purpose of enhancing communication among large groups, allowing for
benchmarking of operations, promoting quality clinical outcomes, developing
new opportunities, and improving advocacy in the legislative and regulatory
arenas. Active LUGPA members have 10 or more physicians in their group
practices, and associate members have at least five, but fewer than 10,
physicians in their group practices.
LUGPA’s mission is to provide urological surgeons practicing within
the context of integrated group practices the means to access resources,
technology and management tools that will enable them to furnish all services
needed to care for patients with acute and chronic illnesses of the genitourinary
system in an efficient, cost-effective and clinically superior manner,
while using data collection to create parameters that demonstrate quality
and value to patients, vendors, third party payors, legislators, and regulatory agencies.